A Phase 1, Single-Dose Study to Assess the Relative Bioavailability, Absolute Bioavailability, and Tolerability of LY3074828 Formulations in Healthy Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Sep 2017
At a glance
- Drugs Mirikizumab (Primary) ; Mirikizumab (Primary)
- Indications Crohn's disease; Plaque psoriasis; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 18 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 18 May 2017 Planned End Date changed from 1 Oct 2017 to 1 Nov 2017.
- 18 May 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Nov 2017.